All In Biotech

Drug Trial Radar · NCT05361668

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid Syndrome

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Apr 22, 2022

Primary completion

Mar 7, 2024

Study completion Feb 24, 2026

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
May 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.

Conditions

  • Carcinoid Syndrome
  • Carcinoid
  • Carcinoid Tumor
  • Carcinoid Tumor of Ileum
  • Carcinoid Tumor of Cecum
  • Carcinoid Syndrome Diarrhea
  • Carcinoid Intestine Tumor
  • Carcinoid Tumor of Liver
  • Carcinoid Tumor of Pancreas

Interventions

  • Randomized: 40 mg PaltusotineDrug

    Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)

  • Randomized: 80 mg PaltusotineDrug

    Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)Time frame: First dose of investigational medicine to End of Randomized Treatment Phase (8 weeks)

Locations

35 sites in 7 countries. Site status is shown where the registry gives one.

  • Crinetics Study Site

    Los Angeles, California

  • Crinetics Study Site

    Los Angeles, California

  • Crinetics Study Site

    Newport Beach, California

  • Crinetics Study Site

    Stanford, California

  • Crinetics Study Site

    Miami, Florida

  • Crinetics Study Site

    Iowa City, Iowa

  • Crinetics Study Site

    Lexington, Kentucky

  • Crinetics Study Site

    New Orleans, Louisiana

  • Crinetics Study Site

    Boston, Massachusetts

  • Crinetics Study Site

    Rochester, Minnesota

  • Crinetics Study Site

    New York, New York

  • Crinetics Study Site

    Stony Brook, New York

  • Crinetics Study Site

    Cleveland, Ohio

  • Crinetics Study Site

    Columbus, Ohio

  • Crinetics Study Site

    Houston, Texas

  • Crinetics Study Site

    CABA, Argentina

  • Crinetics Study Site

    CABA, Argentina

  • Crinetics Study Site

    CABA, Buenos Aires, Argentina

  • Crinetics Study Site

    CABA, Buenos Aires, Argentina

  • Crinetics Study Site

    CABA, Buenos Aires, Argentina

  • Crinetics Study Site

    Rio de Janeiro, Brazil

  • Crinetics Study Site

    Fortaleza, Ceará, Brazil

  • Crinetics Study Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Crinetics Study Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Crinetics Study Site

    Criciúma, Santa Catarina, Brazil

  • Crinetics Study Site

    São Paulo, São Paulo, Brazil

  • Crinetics Study Site

    Toronto, Canada

  • Crinetics Study Site

    Mexico City, Cuauhtemoc, Mexico

  • Crinetics Study Site

    Querétaro City, Querétaro, Mexico

  • Crinetics Study Site

    Querétaro City, Querétaro, Mexico

  • Crinetics Study Site Peru #1

    Lima, Peru

  • Crinetics Study Site Peru #2

    Lima, Peru

  • Crinetics Study Site

    Katowice, Poland

  • Crinetics Study Site

    Warsaw, Poland

  • Crinetics Study Site

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.